GH Research PLC (GHRS)

Market Cap	332.93M
Revenue (ttm)	n/a
Net Income (ttm)	-40.90M
Shares Out	52.02M
EPS (ttm)	-0.79
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	37,761
Open	6.21
Previous Close	6.24
Day's Range	6.10 - 6.50
52-Week Range	5.70 - 14.64
Beta	0.91
Analysts	Strong Buy
Price Target	40.67 (+557.03%)
Earnings Date	Nov 9, 2023

About GHRS

GH Research PLC, a clinical-stage biopharmaceutical company, engages in developing various therapies to treat psychiatric and neurological disorders. The company develops 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) therapies for the treatment of patients with treatment-resistant depression (TRD). Its lead program is GH001, an inhalable mebufotenin product candidate that has completed two Phase 1 clinical trials and Phase 1/2 clinical trial in patients with TRD. The company also develops GH002, an intravenous mebufotenin product candidate; and ...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Jun 25, 2021
• Employees: 32
• Stock Exchange: NASDAQ
• Ticker Symbol: GHRS

Analyst Forecast

According to 3 analysts, the average rating for GHRS stock is "Strong Buy." The 12-month stock price forecast is $40.67, which is an increase of 557.03% from the latest price.

Price Target

$40.67

(557.03% upside)

Analyst Consensus: Strong Buy